Analyst Austin Moeller from Canaccord Genuity maintained a Buy rating on Cibus and keeping the price target at $15.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Austin Moeller has given his Buy rating due to a combination of factors that highlight Cibus’s strategic focus and financial prudence. The company has made significant efforts to streamline its operations by reducing its workforce, which is expected to lower cash burn by approximately $30 million by 2026. This move is seen as a wise decision to conserve resources while maintaining focus on their core projects.
Furthermore, Cibus is targeting substantial revenue growth from its gene-edited trait and sustainable ingredient projects. The company anticipates initiating commercial trait royalties in 2027, potentially scaling to around $200 million annually. Additionally, Cibus expects to start generating revenue from a biofragrance partnership by late 2025. These strategic initiatives, coupled with prudent financial management, underpin the Buy rating and the $15 price target.